![](https://investorshub.advfn.com/uicon/223591.png?cb=1493388194)
Monday, October 20, 2014 11:53:09 AM
![frown](/images/emoticon05.gif)
~ dCellVax News = OOOh..Crap! = Just~a~Submission!!
![frown](/images/emoticon05.gif)
...well this means 30 days until the FDA gives an actual IND #,, if then,, but we will say they get it,,, so then another 30 days for the FDA (Remember this is the Gov'n't
![frown](/images/emoticon05.gif)
![frown](/images/emoticon05.gif)
ZZZZZZZZZZZZzzzzzzzzzz!!!
![frown](/images/emoticon05.gif)
Basically RGBP has NOTHING in the Pipeline to be excited about until the week of Dec 8th...if FrRreaking then!!!!!!
![frown](/images/emoticon05.gif)
---
SAN DIEGO, CA, Oct 08, 2014 (Marketwired via COMTEX) -- Regen BioPharma Inc. RGBP, announced today the filing of an Investigational New Drug (IND) application
![wink](/images/emoticon03.gif)
![frown](/images/emoticon05.gif)
"Today marks a significant milestone for Regen BioPharma Inc., by filing our second IND application, we are accomplishing our original mission statement, which was to accelerate translation of nascent intellectual property from academia into viable therapeutic products," said David Koos, President and CEO of Regen BioPharma. "We are thankful for Dr. Wei-Ping Min and his team at the University of Western Ontario, who have worked diligently with us over the last 18 months in making this IND application a reality."
dCellVax has been developed based on US patent #8,389,708, acquired from Dr. Wei-Ping Min, as well as a collaboration between Dr. Min and the Company's Chief Science Officer Dr. Thomas Ichim, which has spanned over 10 years. Together Dr. Min and Dr. Ichim have published 37 peer reviewed papers in the area of gene silencing and immune modulation. Additionally, the Company obtained an exclusive license from Benitec Biopharma covering the use of RNA interference to silence the molecule that is being inhibited in the generation of dCellVax.
"The dCellVax approach to cancer is different than other gene silencing therapeutics currently in development. Most companies use gene silencing to block abnormal genes found in the tumor (oncogenes). Unfortunately, to get tumor cure with this approach, one would need to silence 100% of the cancer cells, otherwise, the remaining cells will continue to multiply. Achieving silencing in 100% of cancer cells is next to impossible. With the dCellVax approach, we are silencing genes that suppress the immune response to cancer. With this approach, even achieving silencing in 20% of immune cells is enough to cause an increased immune response, which hopefully will overcome the tumor," said Dr. Ichim. "To our knowledge this is the first time that gene silencing is being proposed as a means of overcoming immune suppression in a clinical situation."
About Regen BioPharma Inc.: Regen BioPharma Inc. RGBP, -18.17% is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (pinksheets:BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials.
Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
![frown](/images/emoticon05.gif)
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
Phone: 619.702.1404
Fax: 619.330.2328
www.regenbiopharma.com
SOURCE: Regen BioPharma Inc.
(C) 2014 Marketwire L.P. All rights reserved.
___________
As always,, the above Post is "Just My Opinion!"
![wink](/images/emoticon03.gif)
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM